Physician profile
Thomas White
NPI 1174612741
$1,894.04
in general payments reported to CMS, 2019-2025
14 companies · $44.35 in 2025
The $44.35 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $75.35 · 2021: $49.50 · 2022: $14.89 · 2023: $263 · 2024: $1,447 · 2025: $44.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,038 · Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,037.73 |
| Food and Beverage | $716.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,135.89 | 2023-2024 | Senza |
| Medtronic, INC. | $344.12 | 2023-2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $100.14 | 2020-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.92 | 2024 | Xifaxan |
| Janssen Biotech, INC. | $37.12 | 2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $33.89 | 2024 | Entyvio |
| Allergan, INC. | $30.80 | 2020 | |
| Globus Medical, INC. | $28.38 | 2025 | Senza |
| Ardelyx, INC. | $24.94 | 2024 | Ibsrela |
| Relievant Medsystems, INC. | $21.38 | 2023 | Intracept |
| Ibsa Pharma INC. | $19.97 | 2023 | Tirosint, Licart |
| Lilly USA, LLC | $15.54 | 2021 | |
| Merck Sharp & Dohme LLC | $14.89 | 2022 | |
| Depuy Synthes Sales INC. | $14.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.